Type: Selective monoclonal antibody against Angiopoietin 2 (Ang2)
Status: Eli Lilly is assessing LY3127804 in a Phase II trial (NCT04342897) in pneumonia patients hospitalized with COVID-19 who are at a higher risk of progressing to acute respiratory distress syndrome (ARDS). The study was recruiting patients as of the most recent May 28 update on ClincialTrials.gov.
Lilly’s chief scientific officer Daniel M. Skovronsky, MD, PhD, told analysts April 23 that LY3127804 was its most advanced antibody candidate against COVID-19, adding that it “shows potent neutralization of live virus, and has now entered GMP manufacturing.”
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: